Introduction
Nonalcoholic fatty liver disease (NAFLD) is a form of chronic liver disease with hist opathologic features of typical alcoholinduced chronic liver disease that develops in individuals who do not consume alcohol excessively 1) . Since Ludwig et al. 2) described nonalcoholic steatohepatitis (NASH) in 1980, there have been remarkable advances in diagnosing NAFLD. The disease spectrum of NAFLD ranges from simple steatosis to NASH, nonalcoholic hepatic fibrosis, and nonalcoholic cirrhosis, and NASH progresses towards cirrhosis, even in children 35) . Therefore, early detection of hepatic fibrosis and accurate diagnosis of NAFLD are essential, and NASH, fibrosis, and cirrhosis should be distinguished from benign simple steatosis in obese children suspected to have NAFLD. Typically, the diagnosis of NASH is based on clinical exclusion of alcohol or drug intake, followed by serologic exclusion of other underlying liver diseases, and, finally, percutaneous liver biopsy. Percutaneous liver biopsy is regarded as the gold standard for diagnosing NAFLD, even in children, because a definite NAFLD diagnosis requires histological data such as macrovesicular steatosis, necroinflammation, and hepatic fibrosis 6) . As Roberts 7) suggested in 2007, candidate criteria for liver biopsy in suspected pediatric NAFLD include factors such as an age of less than 10 years, hepatosplenomegaly, highly increased serum aminotransferase level, severe insulin resistance, comorbid chronic liver diseases, and family history. However, the use of liver biopsy is limited in the pediatric population because of its invasiveness and the fact that the histologic features of pediatric NASH are somewhat different from those of adult NASH 8, 9) .
Recently, noninvasive diagnostic methods, including imaging studies for detecting steatosis or fibrosis, and biomarkers of oxidative stress, inflammation, hepatocyte apoptosis, and hepatic fibrosis have been introduced to diagnose the spectrum of NAFLD 10, 11) . Additionally, noninvasive markers of hepatic fi brosis and noninvasive hepatic fibrosis scores have also been developed and applied for evaluating the severity of hepatic fibrosis, mainly in adults 1214) . To date, only a limited number of studies have examined noninvasive biochemical markers of hepatic fibrosis for pediatric NAFLD 1517) and only a few studies have been performed on previously suggested fibrosis scores or NAFLDrelated hepatic fibrosis scores in children 1820) . Although data and validation studies in the pediatric population are still lacking, these non invasive modalities can also be applied for pediatric NAFLD. In this review, noninvasive clinical and laboratory parameters as possible clues of NAFLD, noninvasive imaging studies for detecting hepatic steatosis (and possibly fibrosis), newly de veloped noninvasive biomarkers for diagnosing NAFLD, and noninvasive hepatic fibrosis scores indicating the severity of hepatic fibrosis will be discussed, with a primary focus on pediatric NAFLD.
Clinical and laboratory clues to NAFLD in obese children
Most cases of NAFLD in obese children and adolescents are incidentally detected by health checkups at schools or hospitals. Most patients with NAFLD are asymptomatic, except for nonspecific clinical symptoms or signs such as easy fatig ability and right upper quadrant abdominal discomfort or hepatomegaly and acanthosis nigricans in some patients 21, 22) .
There are no clinical features definitely indicative of NAFLD in obese children. However, some clinical features such as obstructive sleep apnea or acanthosis nigricans may be signifi cantly correlated with NAFLD 23) . Increased levels of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in obese patients are well known predictors of NAFLD, particularly NASH, although serum aminotransferase levels sometimes remain within a normal range despite the presence of NAFLD 21) . Mildly elevated levels of alkaline phosphatase or gamma glutamyl transpeptidase (GGT) have been associated with NAFLD 21) . However, the levels of these enzymes do not reflect the severity of steatosis or hepatic fibrosis in patients with NAFLD.
According to a recent study on pediatric NASH 24) , most NAFLD patients were obese children with a body mass index (BMI) higher than the 95th percentile, and other demographic fea tures were not significantly different among the 3 groups examined (no NASH, adulttype NASH, and definite NASH), although age and ethnicity differed between pediatrictype NASH and definite NASH. Increased levels of serum AST and GGT were significant predictors of NAFLD among the 3 groups, as were age, prothrombin time, and insulin resistance between 2 groups 24) . Additionally, increased serum AST levels, white blood cell count, and decreased hematocrit levels were found to be significant predictors of moderate fibrosis in that study 24) . In contrast, a multicenter study in 2009 showed that none of the clinical features, including BMI or comorbid dis eases, were significantly correlated with the stage of fibrosis; laboratory markers were also not correlated, except for serum AST levels 25) . The serum AST levels were correlated with the stage of fibrosis and could be used to distinguish significant fibrosis from no or mild fibrosis 25) . However, in this study, the authors concluded that AST is a good predictor of severe fibrosis in children with NAFLD, based on the low value (0.63) obtained for the area under the receiver operating curve (AUROC) 25) . In our recent studies, no single clinical or laboratory parameters reflected the presence or severity of hepatic fibrosis in children with NAFLD 18) , except for BMI, which was significantly different among children with simple steatosis, type 1 adult NASH, and type 2 pediatric NASH 9) . Thus, noninvasive tools beyond clinical or laboratory markers are required to diagnose NAFLD in children, such as noninvasive imaging studies, biomarkers, or hepatic fibrosis scores.
Noninvasive imaging studies for pediatric NAFLD
Noninvasive imaging modalities for NAFLD include abdo minal ultrasonography (USG), abdominal computed tomography (CT), magnetic resonance imaging (MRI), fibroscan (hepatic ela sto graphy), magnetic resonance (MR) elastography, and MR spectroscopy 11) . Among noninvasive imaging techniques, abdominal USG has some advantages because it is a safe and economic modality showing a wide range of sensitivity and specificity in screening for the presence of hepatic steatosis in patients with NAFLD. Thus, abdominal USG is frequently used to detect the presence of fatty liver and to evaluate the degree of hepatic steatosis in the clinical field, although the diagnostic accuracy of liver USG in children has not yet been determined 26) . Ultrasonographic criteria for assessing hepatic steatosis include hepatorenal echo contrast, liver brightness, intrahepatic vessel blurring, and visualization of the liver parenchyma and diaphragm 11) .
According to a recent study examining the clinical utility of ultrasonographic quantification of hepatic steatosis, liver USG is a useful tool for quantifying hepatic steatosis in children suspected to have NAFLD, because the degree of steatosis on Korean J Pediatr 2013;56(2):45-51
USG was strongly correlated with the steatosis grade obtained on liver histopathological analysis 26) . Unenhanced abdominal CT is useful for detecting the presence of fatty liver and visceral adiposity and sufficiently sensitive to quantify hepatic steatosis 27) . The diagnostic accuracy of abdominal CT was relatively high in cases where hepatic steatosis was found to be present in more than 30% of the liver when a liverspleen house field unit ratio was applied 28) . However, CT
is not recommended for the pediatric population due to the ra diation hazard. Compared with abdominal CT, MRI is a highly accurate ima ging modality that is useful for identifying and quantifying hepatic steatosis safely, even in children, without radiation hazard 29) . The disadvantages of using MRI for diagnosing NAFLD include high costs and limitations in patients with claustrophobia, metallic devices, or iron overload 30) . Clinically, abdominal USG, CT, and MRI have some limita tions because these methods cannot accurately differentiate between simple steatosis and NASH and cannot confirm the presence or stages of hepatic fibrosis 11) . Recently introduced methods such as fibroscan, MR elastography, and MR spectros copy are promising modalities expected to overcome the limi tations of conventional imaging studies in detecting hepatic fibrosis or steatosis. According to recent studies, fibroscan (transient elastography) using an ultrasonographic technique can be applied to nonin vasively detect liver fibrosis by measuring liver stiffness in both adults and children, although this method has some disadvantages, including decreased performance with increase in BMI and also expensive equipment 31, 32) . MR elastography, introduced for the assessment of hepatic fibrosis in adult patients with NAFLD, is a noninvasive imaging technique that can also be applied in children, despite some limitations 33, 34) .
Additionally, 1HMR spectroscopy may be an alternative noninvasive method for identifying and measuring hepatic fat content in patients with NAFLD 35) . Regarding the noninvasive diagnosis of pediatric NAFLD by using imaging techniques, in 2012, the Hepatology Committee of European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) concurred that most studies exami ning various imaging methods had been performed with adult NAFLD patients and that only a few studies had been performed for a large group of pediatric NAFLD patients 36) .
The committee reached a consensus in that abdominal USG is a safe method with a limited ability to quantify steatosis or fibrosis and that abdominal MRI is a very expensive, rapid, and reproducible method for measuring steatosis and fibrosis after some modifications 36) . Fibroscan is not yet universally recommended for pediatric NAFLD 36) .
Noninvasive biomarkers of NAFLD in children
The ideal biomarkers for NAFLD are those that would be simple and easy to measure, costeffective, accurate in diag nosing NAFLD, capable of helping evaluate the stage of fibrosis and to monitor treatment response, and validated in a large or multicenter study 10) . There are 4 major categories of noninva sive biomarkers that can be used to indicate NAFLD not only in adults but also in the pediatric population: hepatic inflam mation, oxidative stress, hepatocyte apoptosis, and hepatic fibrosis 10, 11, 23, 36) .
Category I. Biomarkers of hepatic inflammation
Beyond laboratory markers of systemic inflammation such as Creactive protein (CRP) or high sensitive CRP, cytokines have been suggested as possible biomarkers of hepatic inflam mation in both adults and children with NASH 10, 23, 36) . Increased levels of serum tumor necrosis factor (TNF)α and interleukin 6, which are proinflammatory cytokines, were noted in patients with NAFLD, and increased levels of leptin and decreased levels of adiponectin, which are adipocytokines, are also reported to be related to NAFLD development in adults and children.
Controversy exists regarding the elevation of serum TNFα levels in children with NAFLD: one study reported a correlation between serum TNFα levels and NAFLD activity scores (NASs) obtained on liver biopsy 37) , whereas other studies, including our recent study, reported no significant differences in serum TNFα levels among different NAFLD groups 38) . The serum concentration of leptin, an adipokine that is produced in adipose tissue and acts as a marker of insulin resistance, is also contro versial in pediatric NAFLD. This is because only a few studies have reported a correlation between serum leptin levels and the histological features of NAFLD or higher serum leptin levels in children with NAFLD than in controls 37, 39) , whereas other studies have reported no significant difference in serum leptin levels 40) . Adiponectin is also an adipokine and acts as a marker of insulin sensitivity. In some studies on pediatric NAFLD, serum adiponectin levels were found to decrease in obese children with elevated serum ALT levels and in obese children with fatty liver confirmed using USG 39, 41) . In our previous study on children with histopathologically confirmed NAFLD, serum adiponectin levels were lower in patients with NASH than in controls and patients with simple steatosis 40) . Recently, retinolbinding protein 4 (RBP4), which is an another adipocytokine associated with insulin resistance, was introduced as a possible noninvasive marker in children with NAFLD, indicating that circulating RBP4 is potentially related with the degree of liver damage in pediatric NAFLD 5, 42) . These data suggest that measuring various biomarkers of hepatic inflammation such as proinflammatory cytokines and adipocytokines may be useful for detecting NAFLD and for identifying NASH among the spectrum of NAFLD in children. However, to date, there is a lack of data to support the widespread clinical application of these cytokines for diagnosing NASH in children.
Category II. Biomarkers of oxidative stress
According to a 2hit hypothesis as a possible mechanism for the pathogenesis of NAFLD 42) , the first hit for developing NAFLD is the accumulation of macrovesicular fat in the liver, causing hepatic steatosis, and the second hit mainly includes oxidative stress producing excessive reactive oxidative species and free radicals via mitochondrial and peroxisomal pathways in the liver, thereby causing hepatocyte injury, inflammation, and fibrosis. Thus, measuring biomarkers of oxidative stress is expected to reflect NAFLD status; these biomarkers include lipid peroxidation products, antioxidant glutathione, or protein oxidation products 10) . According to a recent study by Bell et al. 43) , hepatic malon dialdehyde levels for hepatic lipid peroxidation were higher in children with biopsyconfirmed NAFLD than in controls or children with hepatitis C infection, although there was no significant difference between hepatic cytochrome P450 2E1 protein levels in both groups. In a 2008 study, protein glutathi onylation, occurring as a response to oxidative stress, was found to have increased in the liver tissue of children with NAFLD; furthermore, it was found to be correlated with NASH and fibrosis 44) . Nobili et al. 45) reported that oxidative stress parameters, including the levels of serum protein carbonyls, hepatic 8hydroxy2deoxyguanosine, and circulating anti malondialdehyde adduct human serum albumin (antiMDA HSA) immunoglobulin G antibody, were elevated in children with NAFLD and that antiMDAHSA levels correlated with NAS, reflecting the severity of NASH on liver biopsy. The results of these studies indicate that biomarkers of oxidative stress may be promising parameters for evaluating pediatric NAFLD, although these parameters remain controversial for adults 46) .
Further studies on clinically available serum biomarkers of oxidative stress are required.
Category III. Biomarkers of apoptosis
Recently, cytokeratin18 (CK18), which is a marker of hepato cyte apoptosis, has been regarded as the most promising bio marker for NASH. Some studies in adults and children have reported the role of CK18 in differentiating NASH from benign simple steatosis 4750) . CK18 levels were significantly higher in children with suspected NAFLD than in controls, indicating that CK18 is the best single independent predictor of NAFLD in children 49) . Even in biopsyproven pediatric NAFLD, the level of the CK18 fragment was higher in children with NAFLD than in controls 50) . Moreover, the CK18 levels were higher in children with NASH than in those with simple steatosis, and CK 18 distinguished significant fibrosis from no or mild fibrosis in children 50) . Therefore, CK18, a biomarker of apoptosis, is a good predictor of NASH and hepatic fibrosis, even in the pe diatric population.
Category IV. Biomarkers of hepatic fibrosis
Ideal hepatic fibrosis biomarkers would be those that are liver specific and whose tests are easy to perform; the levels of these biomarkers would be minimally altered by biliary or urinary excretion or metabolism and would be reflective of hepatic fibrosis from any chronic liver injury, sufficiently sensitive to stratify stages of hepatic fibrosis, associated with progression or regression of hepatic fibrosis, and able to predict clinical outcome 13) . Biomarkers of hepatic fibrosis or fibrogenesis have been suggested, including tumor growth factorβ (TGFβ), hyaluronic acid, laminin, type IV collagen, and other extra cellular matrix components, although there are some limitations to these mo lecules 10) . Among these biomarkers, serum TGFβ levels showed no significant relationship with stages of fibrosis according to histological results obtained for adults 51) . A previous study on tissue inhibitor of metalloproteinase1 (TIMP1) and hyaluronic acid showed that both serum TIMP1 and hyaluronic acid levels were significantly different in adult patients with NASH 52) . In a pediatric study, hyaluronic acid levels of ≥1,200 ng/mL ruled out fibrosis (stage 0) and levels that were ≥2,100 ng/mL significantly distinguished advanced fibrosis (stage 2 or more) in children, indicating that hyaluronic acid may be a good predictor of hepatic fibrosis not only in adults but also in children 16) . Type IV collagen has been investigated only in adult patients with NASH and the results of a study suggested a weak but significant correlation between type IV collagen levels and stages of fibrosis; in this study, higher type IV collagen levels were seen in adults with advanced fibrosis (stage 3 or more) than in those with mild fibrosis 53) . However, not much data are available regarding the application of type IV collagen for assessing hepatic fibrosis stages. Thus, further studies are required to develop a single bio marker of hepatic fibrosis that can detect the presence of fibro sis and discriminate advanced fibrosis from no or mild fibrosis.
Noninvasive hepatic fibrosis scores of NAFLD in children
To date, a variety of noninvasive hepatic fibrosis scores, Korean J Pediatr 2013;56(2):45-51 involving of one or more clinical parameters and laboratory markers, have been developed and applied in adults with NAFLD to differentiate NASH from benign simple steatosis, particularly in terms of the presence of hepatic fibrosis 14) . The AST/ALT ratio is a commonly used indicator of hepatic fibrosis because it is simple and easy to calculate; however, the diagnostic accuracy of an AST/ALT ratio>1 is very low in children with NAFLD, limiting its routine use as a hepatic fibrosis score 18, 24) . The ASTplatelet ratio index (APRI), which includes AST and platelet count, has primarily been used to predict hepatic fibrosis in various chronic liver diseases in adults and children 54, 55) . In our previous study on pediatric NAFLD, APRI was an excellent predictor of significant hepatic fibrosis (stage 2 or more) in children with biopsyproven NASH 18) . FibroTest, which involves total bilirubin, GGT, α2macroglo bulin, apolipoprotein A1, and haptoglobin levels, may be a good predictor of advanced fibrosis, but it has been evaluated only in adults with NAFLD and not in children 56) . The FIB4 score, which involves age, AST, ALT levels, and platelet count, has been applied in adults with NAFLD and has been found to be a better noninvasive method of scoring fibrosis than other scores 57) . In our recent study published in 2012, FIB4 was first evaluated in children with biopsyconfirmed NAFLD and showed the highest diagnostic accuracy among various noninvasive hepatic fibrosis scores in differentiating significant fibrosis (stage 2 or more) from no or mild fibrosis in pediatric NAFLD 18) . The enhanced liver fibrosis (ELF) test, involving hyaluronic acid, aminoterminal propeptide of type III collagen, and TIMP1, was found to be a good predictor in adult patients with chronic liver disease 58) , and was then also applied to children with NAFLD in order to predict hepatic fibrosis 19) . The ELF test can differentiate significant fibrosis (stage 3 or more) from no or mild fibrosis, with an AUROC of 0.99 for a cutoff of 10.51 in children 19) . The pediatric NAFLD fibrosis index (PNFI) is the only nonin vasive hepatic fibrosis scoring system developed for children with NAFLD and involves age, waist circumference, and serum triglyceride levels 20) . According to previous studies, PNFI is useful for differentiating children with hepatic fibrosis from those without fibrosis with an AUROC of 0.85 and 0.761, re spectively 20, 59) . On combining the PNFI and ELF tests, the AUROC for predicting hepatic fibrosis increased up to 0.944 in children 59) .
Conclusion
Liver biopsy is regarded as the gold standard of diagnosis of NAFLD. However, the use of liver biopsy is clinically limited in children due to its invasiveness. Noninvasive diagnostic methods such as imaging studies, biomarkers of inflammation, oxidative stress, hepatic apoptosis, and hepatic fibrosis, and noninvasive hepatic fibrosis scores may be useful for overcoming these disadvantages. Although these noninvasive methods have not been widely used or validated in pediatric NAFLD, some of them may be applicable for detecting hepatic steatosis and predicting hepatic fibrosis even in children with NAFLD.
